Trial Profile
Beta-hCG + EryThropoietin in Acute Stroke
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2009
Price :
$35
*
At a glance
- Drugs NTx 265 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms BETAS-b
- Sponsors Trillium Therapeutics Inc
- 15 May 2009 Stem Cell Therapeutics announced that the U.S. FDA has issued a formal letter confirming immediate removal of the clinical hold placed on the Phase IIb stroke trial.
- 18 Sep 2008 Stem Cell Therapeutics has received a verbal request (from the US FDA) not to begin trial recruitment yet as data from an unrelated foreign study have highlighted safety concerns associated with epoetin-alfa.
- 11 Jun 2008 New trial record.